Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Kaleido Biosciences, Inc.    KLDO

KALEIDO BIOSCIENCES, INC.

(KLDO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

KALEIDO BIOSCIENCES, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)

01/14/2021 | 07:38am EST

Item 7.01 Regulation FD Disclosure.

The Company is furnishing a corporate presentation, attached as Exhibit 99.1 to this Current Report on Form 8-K, which the Company intends to use from time to time in meetings with investors and others. The corporate presentation will also be available in the investor relations section of the Company's website at http://kaleido.com.



Item 8.01. Other Events

On January 14, 2021, the Company issued a press release announcing interim results from 176 patients enrolled in its controlled non-IND clinical study K031 evaluating Microbiome Metabolic Therapy (MMT™) candidate KB109 when added to Supportive Self-Care for outpatients with mild-to-moderate COVID-19 disease. A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibits 99.1, and 99.2) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.


(d) Exhibits:



Exhibit No.   Description

                Corporate presentation of the Company, dated January 2021, furnished
99.1          herewith
                Press Release issued by the Company, dated January 14, 2021, furnished
99.2          herewith
              Cover Page Interactive Data File (embedded within the Inline XBRL
104           document).





--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about KALEIDO BIOSCIENCES, INC.
02/11Kaleido Biosciences Announces the Exercise of the Underwriters' Option to Pur..
GL
02/09KALEIDO BIOSCIENCES : Piper Sandler Starts Kaleido Biosciences at Overweight Wit..
MT
02/08KALEIDO BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Other Ev..
AQ
02/03Kaleido Biosciences Announces Pricing of Public Offering of Common Stock
GL
02/03Kaleido Biosciences Announces Proposed Public Offering of Common Stock
GL
01/25KALEIDO BIOSCIENCES : Chief Medical Officer Katharine Knobil Steps Down
MT
01/25KALEIDO BIOSCIENCES, INC. : Change in Directors or Principal Officers, Financial..
AQ
01/20Kaleido Biosciences to Present at the Keystone Symposium “Harnessing th..
GL
01/20KALEIDO BIOSCIENCES : Other Events, Financial Statements and Exhibits (form 8-K/..
AQ
01/19KALEIDO BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (for..
AQ
More news